Axel Schambach

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8494395/publications.pdf

Version: 2024-02-01

274 papers	14,192 citations	21215 62 h-index	30277 107 g-index
281 all docs	281 docs citations	281 times ranked	19747 citing authors

#	Article	IF	Citations
1	Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34⁺ cord blood hematopoietic stem cells using a clinically applicable lentiviral vector. Haematologica, 2022, 107, 446-456.	1.7	13
2	Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells. Molecular Therapy - Nucleic Acids, 2022, 27, 810-823.	2.3	8
3	Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy. Cells, 2022, 11, 994.	1.8	18
4	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. Frontiers in Bioengineering and Biotechnology, 2022, 10, 801870.	2.0	13
5	GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Frontiers in Immunology, 2022, 13, 839783.	2.2	20
6	Cell transcriptomic atlas of the non-human primate Macaca fascicularis. Nature, 2022, 604, 723-731.	13.7	81
7	Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase. Science, 2022, 376, 1343-1347.	6.0	34
8	Knockout-Induced Pluripotent Stem Cells for Disease and Therapy Modeling of IL-10-Associated Primary Immunodeficiencies. Human Gene Therapy, 2021, 32, 77-95.	1.4	9
9	The hemogenic endothelium: a critical source for the generation of PSC-derived hematopoietic stem and progenitor cells. Cellular and Molecular Life Sciences, 2021, 78, 4143-4160.	2.4	25
10	Genetic Correction of IL-10RB Deficiency Reconstitutes Anti-Inflammatory Regulation in iPSC-Derived Macrophages. Journal of Personalized Medicine, 2021, 11, 221.	1.1	5
11	Rescue from Pseudomonas aeruginosa Airway Infection via Stem Cell Transplantation. Molecular Therapy, 2021, 29, 1324-1334.	3.7	6
12	Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory. Scientific Reports, 2021, 11, 5294.	1.6	0
13	Retroviral gene therapy in Germany with a view on previous experience and future perspectives. Gene Therapy, 2021, 28, 494-512.	2.3	15
14	Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal. Molecular Therapy - Methods and Clinical Development, 2021, 20, 389-397.	1.8	5
15	Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector. Molecular Therapy - Methods and Clinical Development, 2021, 20, 312-323.	1.8	13
16	A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control <i>scurfy</i> syndrome. Blood, 2021, 137, 2326-2336.	0.6	9
17	Multiple Genes Surrounding <i>Bcl-x_L</i>, a Common Retroviral Insertion Site, Can Influence Hematopoiesis Individually or in Concert. Human Gene Therapy, 2021, 32, 458-472.	1.4	4
18	DNA methylation changes during long-term in vitro cell culture are caused by epigenetic drift. Communications Biology, 2021, 4, 598.	2.0	27

#	Article	IF	Citations
19	An Improved Lentiviral Fluorescent Genetic Barcoding Approach Distinguishes Hematopoietic Stem Cell Properties in MultiplexedIn VivoExperiments. Human Gene Therapy, 2021, 32, 1280-1294.	1.4	5
20	Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing. Frontiers in Immunology, 2021, 12, 684052.	2.2	11
21	Efficient Genetic Safety Switches for Future Application of iPSC-Derived Cell Transplants. Journal of Personalized Medicine, 2021, 11, 565.	1.1	11
22	Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning. Molecular Therapy, 2021, 29, 3383-3397.	3.7	25
23	Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123. Viruses, 2021, 13, 1365.	1.5	16
24	Targeted cytokine delivery: cell therapy to remodel the pre-metastatic niche. Signal Transduction and Targeted Therapy, 2021, 6, 282.	7.1	0
25	Pulmonary transplantation of alpha-1 antitrypsin (AAT)-transgenic macrophages provides a source of functional human AAT in vivo. Gene Therapy, 2021, 28, 477-493.	2.3	5
26	Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. Journal of Hepatology, 2021, 75, 1420-1433.	1.8	70
27	Reprogramming enriches for somatic cell clones with small-scale mutations in cancer-associated genes. Molecular Therapy, 2021, 29, 2535-2553.	3.7	9
28	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 2021, 16, e0255335.	1.1	48
29	A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML. International Journal of Molecular Sciences, 2021, 22, 9411.	1.8	11
30	A first step toward in vivo gene editing in patients. Nature Medicine, 2021, 27, 1515-1517.	15.2	5
31	NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44. Biomedicines, 2021, 9, 1339.	1.4	18
32	Two cases of TÂcell lymphoma following Piggybac-mediated CAR TÂcell therapy. Molecular Therapy, 2021, 29, 2631-2633.	3.7	10
33	Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47^{phox}-Deficient Chronic Granulomatous Disease. Human Gene Therapy, 2021, 32, 949-958.	1.4	4
34	Generation of hiPSC-derived low threshold mechanoreceptors containing axonal termini resembling bulbous sensory nerve endings and expressing Piezo1 and Piezo2. Stem Cell Research, 2021, 56, 102535.	0.3	4
35	Gene Therapy â€œMade in Germanyâ€• A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy. Human Gene Therapy, 2021, 32, 987-996.	1.4	3
36	Generation of an NFÎºB-Driven Alpharetroviral â€œAll-in-Oneâ€•Vector Construct as a Potent Tool for CAR NK Cell Therapy. Frontiers in Immunology, 2021, 12, 751138.	2.2	11

#	Article	IF	Citations
37	Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis. Haematologica, 2020, 105, 1147-1157.	1.7	7
38	RAD50 regulates mitotic progression independent of DNA repair functions. FASEB Journal, 2020, 34, 2812-2820.	0.2	9
39	Conditional Immortalization of Lymphoid Progenitors via Tetracycline-Regulated LMO2 Expression. Human Gene Therapy, 2020, 31, 183-198.	1.4	3
40	ExÂVivo/InÂvivo Gene Editing in Hepatocytes Using â€œAll-in-Oneâ€•CRISPR-Adeno-Associated Virus Vectors with a Self-Linearizing Repair Template. IScience, 2020, 23, 100764.	1.9	33
41	Inducible Forward Programming of Human Pluripotent Stem Cells to Hemato-endothelial Progenitor Cells with Hematopoietic Progenitor Potential. Stem Cell Reports, 2020, 14, 122-137.	2.3	27
42	Differential Transgene Silencing of Myeloid-Specific Promoters in the AAVS1 Safe Harbor Locus of Induced Pluripotent Stem Cell-Derived Myeloid Cells. Human Gene Therapy, 2020, 31, 199-210.	1.4	31
43	Competitive sgRNA Screen Identifies p38 MAPK as a Druggable Target to Improve HSPC Engraftment. Cells, 2020, 9, 2194.	1.8	3
44	EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal. Cell Death and Disease, 2020, 11, 878.	2.7	4
45	Use of Cell and Genome Modification Technologies to Generate Improved â€œOff-the-Shelfâ€•CAR T and CAR NK Cells. Frontiers in Immunology, 2020, 11, 1965.	2.2	85
46	Î²-Catenin safeguards the ground state of mousepluripotency by strengthening the robustness of the transcriptional apparatus. Science Advances, 2020, 6, eaba1593.	4.7	10
47	Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT Phase 3. EBioMedicine, 2020, 57, 102862.	2.7	22
48	CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. , 2020, 8, e000736.		27
49	Cooperating, congenital neutropeniaâ€“associated Csf3r and Runx1 mutations activate pro-inflammatory signaling and inhibit myeloid differentiation of mouse HSPCs. Annals of Hematology, 2020, 99, 2329-2338.	0.8	5
50	Synthetic Notch-Receptor-Mediated Transmission of a Transient Signal into Permanent Information via CRISPR/Cas9-Based Genome Editing. Cells, 2020, 9, 1929.	1.8	3
51	Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy. Molecular Therapy - Methods and Clinical Development, 2020, 17, 589-600.	1.8	39
52	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia, 2020, 34, 2951-2963.	3.3	13
53	Design and Characterization of an â€œAll-in-Oneâ€•Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines. Cancers, 2020, 12, 375.	1.7	68
54	Lentiviral gene therapy and vitamin B3 treatment enable granulocytic differentiation of G6PC3-deficient induced pluripotent stem cells. Gene Therapy, 2020, 27, 297-306.	2.3	8

#	Article	IF	Citations
55	Challenges and advances in translating gene therapy for hearing disorders. Expert Review of Precision Medicine and Drug Development, 2020, 5, 23-34.	0.4	4
56	Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID. Molecular Therapy - Methods and Clinical Development, 2020, 17, 666-682.	1.8	37
57	Targeted Integration of Inducible Caspase-9 in Human iPSCs Allows Efficient in vitro Clearance of iPSCs and iPSC-Macrophages. International Journal of Molecular Sciences, 2020, 21, 2481.	1.8	12
58	CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer. Cellular Signalling, 2020, 73, 109672.	1.7	28
59	Gene therapy as a possible option to treat hereditary hearing loss. Medizinische Genetik, 2020, 32, 149-159.	0.1	2
60	Cytokine Selection of MSC Clones with Different Functionality. Stem Cell Reports, 2019, 13, 262-273.	2.3	22
61	Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical Application. Molecular Therapy - Methods and Clinical Development, 2019, 14, 134-147.	1.8	37
62	Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID. Molecular Therapy - Methods and Clinical Development, 2019, 15, 232-245.	1.8	18
63	Umbilical cord as a long-term source of activatable mesenchymal stromal cells for immunomodulation. Stem Cell Research and Therapy, 2019, 10, 285.	2.4	25
64	Targeted Repair of p47-CGD in iPSCs by CRISPR/Cas9: Functional Correction without Cleavage in the Highly Homologous Pseudogenes. Stem Cell Reports, 2019, 13, 590-598.	2.3	20
65	Hematopoietic Stem Cell-Targeted Neonatal Gene Therapy with a Clinically Applicable Lentiviral Vector Corrects Osteopetrosis in oc/oc Mice. Human Gene Therapy, 2019, 30, 1395-1404.	1.4	17
66	Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering. Human Gene Therapy Methods, 2019, 30, 102-120.	2.1	43
67	Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 660.	1.8	70
68	Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killerâ€"Based â€œOff-the-Shelfâ€•Acute Myeloid Leukemia Immunotherapies. Human Gene Therapy, 2019, 30, 381-401.	1.4	36
69	High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Frontiers in Immunology, 2019, 10, 3123.	2.2	67
70	Chimeric antigen receptorâ€"induced BCL11B suppression propagates NK-like cell development. Journal of Clinical Investigation, 2019, 129, 5108-5122.	3.9	16
71	Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease. Human Gene Therapy Clinical Development, 2018, 29, 69-79.	3.2	31
72	Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency. Molecular Therapy - Methods and Clinical Development, 2018, 9, 257-269.	1.8	38

#	Article	IF	Citations
73	T-cell gene therapy for perforin deficiency correctsÂcytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations. Journal of Allergy and Clinical Immunology, 2018, 142, 904-913.e3.	1.5	44
74	Impaired IFNÎ³-Signaling and Mycobacterial Clearance in IFNÎ³R1-Deficient Human iPSC-Derived Macrophages. Stem Cell Reports, 2018, 10, 7-16.	2.3	25
75	Pooled Generation of Lentiviral Tetracycline-Regulated microRNA Embedded Short Hairpin RNA Libraries. Human Gene Therapy Methods, 2018, 29, 16-29.	2.1	3
76	Refined sgRNA efficacy prediction improves large- and small-scale CRISPRâ€“Cas9 applications. Nucleic Acids Research, 2018, 46, 1375-1385.	6.5	213
77	Targeting NSG Mice Engrafting Cells with a Clinically Applicable Lentiviral Vector Corrects Osteoclasts in Infantile Malignant Osteopetrosis. Human Gene Therapy, 2018, 29, 938-949.	1.4	12
78	Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy. Molecular Therapy - Methods and Clinical Development, 2018, 8, 21-30.	1.8	34
79	Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling Î²AS3 Globin for Gene Therapy for Sickle Cell Disease. Molecular Therapy - Methods and Clinical Development, 2018, 11, 167-179.	1.8	16
80	Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections. Nature Communications, 2018, 9, 5088.	5.8	105
81	Engineering CAR-T Cells for Improved Function Against Solid Tumors. Frontiers in Immunology, 2018, 9, 2493.	2.2	67
82	Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout. Molecular Therapy - Nucleic Acids, 2018, 13, 256-274.	2.3	34
83	Human Teratoma-Derived Hematopoiesis Is a Highly Polyclonal Process Supported by Human Umbilical Vein Endothelial Cells. Stem Cell Reports, 2018, 11, 1051-1060.	2.3	10
84	CRISPR/Cas9 Immunoengineering of Hoxb8-Immortalized Progenitor Cells for Revealing CCR7-Mediated Dendritic Cell Signaling and Migration Mechanisms in vivo. Frontiers in Immunology, 2018, 9, 1949.	2.2	21
85	Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors. Human Gene Therapy, 2018, 29, 1083-1097.	1.4	11
86	EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association. Nucleic Acids Research, 2018, 46, 7662-7674.	6.5	11
87	Fluorescent genetic barcoding for cellular multiplex analyses. Experimental Hematology, 2018, 67, 10-17.	0.2	5
88	A patient-specific induced pluripotent stem cell model for West syndrome caused by ST3GAL3 deficiency. European Journal of Human Genetics, 2018, 26, 1773-1783.	1.4	15
89	Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model. Oncotarget, 2018, 9, 29869-29876.	0.8	1
90	Inhibition of miRNA-212/132 improves the reprogramming of fibroblasts into induced pluripotent stem cells by de-repressing important epigenetic remodelling factors. Stem Cell Research, 2017, 20, 70-75.	0.3	20

#	Article	IF	Citations
91	Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2243-E2252.	3.3	189
92	CSF-1â€“induced Src signaling can instruct monocytic lineage choice. Blood, 2017, 129, 1691-1701.	0.6	21
93	Forced expression of human macrophage colonyâ€stimulating factor in CD34⁺ cells promotes monocyte differentiation in vitro and in vivo but blunts osteoclastogenesis in vitro. European Journal of Haematology, 2017, 98, 517-526.	1.1	6
94	A Lentiviral Fluorescent Genetic Barcoding System for Flow Cytometry-Based Multiplex Tracking. Molecular Therapy, 2017, 25, 606-620.	3.7	16
95	Lentiviral Vectors with Cellular Promoters Correct Anemia and Lethal Bone Marrow Failure in a Mouse Model for Diamond-Blackfan Anemia. Molecular Therapy, 2017, 25, 1805-1814.	3.7	19
96	An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries. Biomaterials, 2017, 139, 102-115.	5.7	24
97	Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy. Molecular Therapy, 2017, 25, 1790-1804.	3.7	32
98	Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease. Molecular Therapy - Methods and Clinical Development, 2017, 5, 241-258.	1.8	36
99	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. Journal of Hepatology, 2017, 67, 237-245.	1.8	26
100	An RNA-targeted therapy for dystrophic epidermolysis bullosa. Nucleic Acids Research, 2017, 45, 10259-10269.	6.5	21
101	The CpG-sites of the CBX3 ubiquitous chromatin opening element are critical structural determinants for the anti-silencing function. Scientific Reports, 2017, 7, 7919.	1.6	8
102	Optimization of Human NK Cell Manufacturing: Fully Automated Separation, ImprovedEx VivoExpansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells. Human Gene Therapy, 2017, 28, 897-913.	1.4	106
103	Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptorâ€“Based Immunotherapy and Chemotherapy. Human Gene Therapy, 2017, 28, 886-896.	1.4	65
104	Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis. Hematology/Oncology Clinics of North America, 2017, 31, 737-752.	0.9	16
105	The non-coding RNA landscape of human hematopoiesis and leukemia. Nature Communications, 2017, 8, 218.	5.8	131
106	Function and Safety of Lentivirus-Mediated Gene Transfer forCSF2RA-Deficiency. Human Gene Therapy Methods, 2017, 28, 318-329.	2.1	16
107	Multimodal Lentiviral Vectors for Pharmacologically Controlled Switching Between Constitutive Single Gene Expression and Tetracycline-Regulated Multiple Gene Collaboration. Human Gene Therapy Methods, 2017, 28, 191-204.	2.1	3
108	Uncoupling the Oncogenic Engine. Cancer Research, 2017, 77, 6060-6064.	0.4	3

#	Article	IF	Citations
109	Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells. Retrovirology, 2017, 14, 34.	0.9	11
110	Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency. Human Gene Therapy, 2017, 28, 112-124.	1.4	44
111	Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells. Blood Advances, 2017, 1, 903-914.	2.5	18
112	Comparison of Tetracycline-regulated Promoters in Lentiviral-based Vectors in Murine Transplantation Studies. Current Gene Therapy, 2016, 16, 242-248.	0.9	4
113	Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival Under Refractoriness Conditions. Molecular Medicine, 2016, 22, 274-285.	1.9	74
114	Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation. Stem Cells, 2016, 34, 797-799.	1.4	6
115	Viral and Synthetic RNA Vector Technologies and Applications. Molecular Therapy, 2016, 24, 1513-1527.	3.7	62
116	Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16074.	1.8	17
117	Improved bi-allelic modification of a transcriptionally silent locus in patient-derived iPSC by Cas9 nickase. Scientific Reports, 2016, 6, 38198.	1.6	29
118	GABP is necessary for stem/progenitor cell maintenance and myeloid differentiation in human hematopoiesis and chronic myeloid leukemia. Stem Cell Research, 2016, 16, 677-681.	0.3	6
119	Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes InÂVivo Attenuates Liver Fibrosis. Cell Stem Cell, 2016, 18, 797-808.	5.2	181
120	Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency. Molecular Therapy, 2016, 24, 1187-1198.	3.7	55
121	Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform. Molecular Therapy, 2016, 24, 1216-1226.	3.7	20
122	Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes. Biomaterials, 2016, 97, 97-109.	5.7	13
123	Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency. Stem Cell Reports, 2016, 7, 292-305.	2.3	23
124	Massive Clonal Selection and Transiently Contributing Clones During Expansion of Mesenchymal Stem Cell Cultures Revealed by Lentiviral RGB-Barcode Technology. Stem Cells Translational Medicine, 2016, 5, 591-601.	1.6	66
125	GTPase domain driven dimerization of SEPT7 is dispensable for the critical role of septins in fibroblast cytokinesis. Scientific Reports, 2016, 6, 20007.	1.6	27
126	Development of Inducible Molecular Switches Based on All-in-One Lentiviral Vectors Equipped with Drug Controlled FLP Recombinase. Methods in Molecular Biology, 2016, 1448, 23-39.	0.4	0

#	Article	IF	Citations
127	Transduction of Murine Hematopoietic Stem Cells with Tetracycline-regulated Lentiviral Vectors. Methods in Molecular Biology, 2016, 1448, 65-76.	0.4	1
128	Establishing a murine xenograft-model for long-term analysis of factors inducing chromosomal instability in myelodysplastic syndrome: Pitfalls and successes. Cancer Genetics, 2016, 209, 258-266.	0.2	2
129	Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG). Molecular and Cellular Proteomics, 2016, 15, 1435-1452.	2.5	51
130	Long noncoding RNA Chast promotes cardiac remodeling. Science Translational Medicine, 2016, 8, 326ra22.	5.8	321
131	Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy. Molecular Therapy, 2016, 24, 678-684.	3.7	175
132	Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nature Biotechnology, 2016, 34, 401-409.	9.4	108
133	Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. Journal of Molecular Medicine, 2016, 94, 83-93.	1.7	65
134	Retroviral Vectors for Cancer Gene Therapy. Recent Results in Cancer Research, 2016, 209, 17-35.	1.8	24
135	Generation of Functional Regulatory T Cells By FOXP3 Gene Transfer into CD4 T Cells from Scurfy Mice and IPEX Patients. Blood, 2016, 128, 2526-2526.	0.6	2
136	New Molecular Surrogate Assay for Genotoxicity Assessment of Gene Therapy Vectors (SAGA). Blood, 2016, 128, 4710-4710.	0.6	4
137	Preclinical Development of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1). Blood, 2016, 128, 4705-4705.	0.6	1
138	Deciphering the impact of parameters influencing transgene expression kinetics after repeated cell transduction with integrationâ€deficient retroviral vectors. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 405-418.	1.1	4
139	Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1). Journal of Experimental and Clinical Cancer Research, 2015, 34, 148.	3.5	5
140	Novel Self-Inactivating Vectors for Reconstitution of Wiskott-Aldrich Syndrome. Current Gene Therapy, 2015, 15, 245-254.	0.9	4
141	Limited niche availability suppresses murine intrathymic dendritic-cell development from noncommitted progenitors. Blood, 2015, 125, 457-464.	0.6	13
142	Lentiviral Gene Therapy Using Cellular Promoters Cures Type 1 Gaucher Disease in Mice. Molecular Therapy, 2015, 23, 835-844.	3.7	55
143	Large-Scale Hematopoietic Differentiation of Human Induced Pluripotent Stem Cells Provides Granulocytes or Macrophages for Cell Replacement Therapies. Stem Cell Reports, 2015, 4, 282-296.	2.3	173
144	A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Research, 2015, 43, 1577-1592.	6.5	70

#	Article	IF	Citations
145	Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections. New England Journal of Medicine, 2015, 372, 2409-2422.	13.9	169
146	The heteromeric transcription factor GABP activates the ITGAM/CD11b promoter and induces myeloid differentiation. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 1145-1154.	0.9	12
147	Reticular dysgenesisâ€“associated AK2 protects hematopoietic stem and progenitor cell development from oxidative stress. Journal of Experimental Medicine, 2015, 212, 1185-1202.	4.2	49
148	Advantages and applications of CAR-expressing natural killer cells. Frontiers in Pharmacology, 2015, 6, 21.	1.6	204
149	Lentiviral vector system for coordinated constitutive and drug controlled tetracycline-regulated gene co-expression. Biomaterials, 2015, 63, 189-201.	5.7	8
150	Expression of the ETS transcription factor GABPÎ± is positively correlated toÂthe BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity inÂvitro. Experimental Hematology, 2015, 43, 880-890.	0.2	5
151	Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model. PLoS Genetics, 2015, 11, e1005239.	1.5	17
152	Responsiveness of Developing T Cells to IL-7 Signals Is Sustained by miR-17â^¼92. Journal of Immunology, 2015, 195, 4832-4840.	0.4	24
153	Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response. Journal of Virology, 2015, 89, 9044-9060.	1.5	25
154	Retrovirus-based vectors for transient and permanent cell modification. Current Opinion in Pharmacology, 2015, 24, 135-146.	1.7	7
155	TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. Biomaterials, 2015, 69, 191-200.	5.7	76
156	Perforin Gene Transfer Into Hematopoietic Stem Cells Improves Immune Dysregulation in Murine Models of Perforin Deficiency. Molecular Therapy, 2015, 23, 737-745.	3.7	41
157	Comparison of Different Cytokine Conditions Reveals Resveratrol as a New Molecule for Ex Vivo Cultivation of Cord Blood-Derived Hematopoietic Stem Cells. Stem Cells Translational Medicine, 2015, 4, 1064-1072.	1.6	23
158	Innovative Hematopoietic Gene-Therapy Concepts for Hereditary Pulmonary Alveolar Proteinosis Utilizing Hematopoietic Stem Cell Derived Macrophages. Blood, 2015, 126, 4417-4417.	0.6	0
159	Dynamic Telomere Shortening and Chromosomal Instability in Irradiated CD34+ Cells Transduced with TP53 Hotspot Mutations R175H, R248W and R249S. Blood, 2015, 126, 4832-4832.	0.6	0
160	No Observation of Chromosomal Instability after Transplantation of RPS14- and TP53-Modified Human HSCs in NSG/NSGS Mice. Blood, 2015, 126, 4797-4797.	0.6	0
161	Enhancement of BMP-2 Induced Bone Regeneration by SDF-1Î± Mediated Stem Cell Recruitment. Tissue Engineering - Part A, 2014, 20, 131112094536009.	1.6	35
162	Gene Correction of Human Induced Pluripotent Stem Cells Repairs the Cellular Phenotype in Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 167-182.	2.5	85

#	Article	IF	Citations
163	FAS-Based Cell Depletion Facilitates the Selective Isolation of Mouse Induced Pluripotent Stem Cells. PLoS ONE, 2014, 9, e102171.	1.1	1
164	Genome-Wide Analysis of Alpharetroviral Integration in Human Hematopoietic Stem/Progenitor Cells. Genes, 2014, 5, 415-429.	1.0	23
165	Clonal Dominance With Retroviral Vector Insertions Near the ANGPT1 and ANGPT2 Genes in a Human Xenotransplant Mouse Model. Molecular Therapy - Nucleic Acids, 2014, 3, e200.	2.3	8
166	Genetic Deletion of SEPT7 Reveals a Cell Type-Specific Role of Septins in Microtubule Destabilization for the Completion of Cytokinesis. PLoS Genetics, 2014, 10, e1004558.	1.5	90
167	Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy. Viruses, 2014, 6, 4811-4838.	1.5	25
168	Gene Therapy for Wiskott-Aldrich Syndromeâ€"Long-Term Efficacy and Genotoxicity. Science Translational Medicine, 2014, 6, 227ra33.	5.8	460
169	miR-155 Is Associated with the Leukemogenic Potential of the Class IV Granulocyte Colony-Stimulating Factor Receptor in CD34+ Progenitor Cells. Molecular Medicine, 2014, 20, 736-746.	1.9	13
170	Primate iPS cells as tools for evolutionary analyses. Stem Cell Research, 2014, 12, 622-629.	0.3	61
171	All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase. Biomaterials, 2014, 35, 4345-4356.	5.7	21
172	Dose response and clonal variability of lentiviral tetracycline-regulated vectors in murine hematopoietic cells. Experimental Hematology, 2014, 42, 505-515.e7.	0.2	11
173	Toward a Safer Integration Profile of MLV-based Retroviral Vectors. Molecular Therapy, 2014, 22, 1405-1406.	3.7	3
174	Transcriptional Pause Release Is a Rate-Limiting Step for Somatic Cell Reprogramming. Cell Stem Cell, 2014, 15, 574-588.	5.2	60
175	Successful RAG1-SCID gene therapy depends on the level of RAG1 expression. Journal of Allergy and Clinical Immunology, 2014, 134, 242-243.	1.5	20
176	RAG1/2 Knockout Pigs with Severe Combined Immunodeficiency. Journal of Immunology, 2014, 193, 1496-1503.	0.4	82
177	Modified Lentiviral LTRs Allow Flp Recombinaseâ€"mediated Cassette Exchange and In Vivo Tracing of â€œFactor-freeâ€•Induced Pluripotent Stem Cells. Molecular Therapy, 2014, 22, 919-928.	3.7	24
178	Genetic reporter analysis reveals an expandable reservoir of OCT4+ cells in adult skin. Cell Regeneration, 2014, 3, 3:9.	1.1	5
179	miR-99a/100âˆ¼125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFÎ² and Wnt signaling. Genes and Development, 2014, 28, 858-874.	2.7	136
180	A Modified Î³-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. New England Journal of Medicine, 2014, 371, 1407-1417.	13.9	358

#	Article	IF	Citations
181	Promoter and lineage independent anti-silencing activity of the A2 ubiquitous chromatin opening element for optimized human pluripotent stem cell-based gene therapy. Biomaterials, 2014, 35, 1531-1542.	5.7	42
182	Differential role of nonhomologous end joining factors in the generation, DNA damage response, and myeloid differentiation of human induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8889-8894.	3.3	34
183	Expanding Flp-RMCE options: the potential of Recombinase Mediated Twin-Site Targeting (RMTT). Gene, 2014, 546, 135-144.	1.0	8
184	Gene therapy cures the anemia and lethal bone marrow failure in a mouse model of RPS19-deficient Diamond-Blackfan anemia. Haematologica, 2014, 99, 1792-1798.	1.7	26
185	Non-integrating gamma-retroviral vectors as a versatile tool for transient zinc-finger nuclease delivery. Scientific Reports, 2014, 4, 4656.	1.6	21
186	Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy. Current Gene Therapy, 2014, 13, 453-468.	0.9	86
187	Safety of Gene Therapy: New Insights to a Puzzling Case. Current Gene Therapy, 2014, 14, 429-436.	0.9	29
188	Expression of the ETS Transcription Factor GABPÎ± Is Correlated to BCR-ABL/ABL ratio in Human CML and Mediates Imatinib Sensitivity. Blood, 2014, 124, 1787-1787.	0.6	0
189	Timely Controlled T Cell Receptor Expression of Genetically Engineered Precursor T Cells Requires Early Transgene Induction for Leukemia Control after Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 657-657.	0.6	0
190	Toward Position-independent Retroviral Vector Expression in Pluripotent Stem Cells. Molecular Therapy, 2013, 21, 1474-1477.	3.7	1
191	Gene therapy on the move. EMBO Molecular Medicine, 2013, 5, 1642-1661.	3.3	238
192	Biosafety Features of Lentiviral Vectors. Human Gene Therapy, 2013, 24, 132-142.	1.4	133
193	Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumor formation in serially transplanted rodents. Hepatology, 2013, 58, 397-408.	3.6	22
194	Alpharetroviral Vector-mediated Gene Therapy for X-CGD: Functional Correction and Lack of Aberrant Splicing. Molecular Therapy, 2013, 21, 648-661.	3.7	30
195	Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. Journal of Experimental Medicine, 2013, 210, 433-443.	4.2	186
196	A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells, 2013, 31, 488-499.	1.4	70
197	Retrovirus-Based mRNA Transfer for Transient Cell Manipulation. Methods in Molecular Biology, 2013, 969, 139-161.	0.4	10
198	Evaluating a Ligation-Mediated PCR and Pyrosequencing Method for the Detection of Clonal Contribution in Polyclonal Retrovirally Transduced Samples. Human Gene Therapy Methods, 2013, 24, 68-79.	2.1	21

#	Article	IF	Citations
199	From Bench to Bedside: Preclinical Evaluation of a Self-Inactivating Gammaretroviral Vector for the Gene Therapy of X-linked Chronic Granulomatous Disease. Human Gene Therapy Clinical Development, 2013, 24, 86-98.	3.2	21
200	Sleeping Beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. Nucleic Acids Research, 2013, 41, 1829-1847.	6.5	75
201	Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice. PLoS Pathogens, 2013, 9, e1003587.	2.1	55
202	Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration. Journal of Virology, 2013, 87, 12721-12736.	1.5	135
203	Investigating Synthetic Lethality Between mTOR Hyperactivation and Cap-Dependent mRNA Translation In a Receptor Tyrosine Kinase Driven Model Of Acute T-Cell Leukemia. Blood, 2013, 122, 3913-3913.	0.6	0
204	Alpharetroviral Self-inactivating Vectors: Long-term Transgene Expression in Murine Hematopoietic Cells and Low Genotoxicity. Molecular Therapy, 2012, 20, 1022-1032.	3.7	61
205	Retroviral Protein Transfer: Falling Apart to Make an Impact. Current Gene Therapy, 2012, 12, 389-409.	0.9	10
206	The phenotype of human STK4 deficiency. Blood, 2012, 119, 3450-3457.	0.6	286
207	Pseudotype-Independent Nonspecific Uptake of Gammaretroviral and Lentiviral Particles in Human Cells. Human Gene Therapy, 2012, 23, 274-286.	1.4	13
208	Modeling abnormal early development with induced pluripotent stem cells from aneuploid syndromes. Human Molecular Genetics, 2012, 21, 32-45.	1.4	66
209	A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage. Cell, 2012, 148, 1001-1014.	13.5	296
210	Intraspinal Injection of Human Umbilical Cord Blood-Derived Cells Is Neuroprotective in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2012, 9, 107-120.	0.8	43
211	Genetic modification of lymphocytes by retrovirus-based vectors. Current Opinion in Immunology, 2012, 24, 598-608.	2.4	40
212	Overcoming reprogramming resistance of Fanconi anemia cells. Blood, 2012, 119, 5449-5457.	0.6	133
213	Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Annals of Hematology, 2012, 91, 1221-1233.	0.8	37
214	Skin tissue generation by laser cell printing. Biotechnology and Bioengineering, 2012, 109, 1855-1863.	1.7	509
215	Pharmacological targeting of the thrombomodulinâ€“activated protein C pathway mitigates radiation toxicity. Nature Medicine, 2012, 18, 1123-1129.	15.2	97
216	Gene Therapy Corrects the Lethal Bone Marrow Failure in a Mouse Model for RPS19-Deficient Diamond-Blackfan Anemia. Blood, 2012, 120, 513-513.	0.6	0

#	Article	IF	Citations
217	the miR-99âˆ¼125 Polycistrons Promote Leukemogenesis in a Cell-Context Dependent Manner by Shifting the Balance Between TGFÎ²- and Wnt-Signaling. Blood, 2012, 120, 109-109.	0.6	1
218	Induced Pluripotent Stem Cells From a Patient with Reticular Dysgenesis Recapitulate Defective Myelopoiesis in-Vitro: A Disease Model to Enhance Our Understanding of a Rare Disease.. Blood, 2012, 120, 2142-2142.	0.6	0
219	Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Human Molecular Genetics, 2011, 20, 3176-3187.	1.4	155
220	Retroviral and Transposon-Based Tet-Regulated All-In-One Vectors with Reduced Background Expression and Improved Dynamic Range. Human Gene Therapy, 2011, 22, 166-176.	1.4	85
221	Development of Novel Efficient SIN Vectors with Improved Safety Features for Wiskottâ€“Aldrich Syndrome Stem Cell Based Gene Therapy. Molecular Pharmaceutics, 2011, 8, 1525-1537.	2.3	63
222	miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. EMBO Reports, 2011, 12, 1153-1159.	2.0	91
223	Polyclonal fluctuation of lentiviral vectorâ€“transduced and expanded murine hematopoietic stem cells. Blood, 2011, 117, 3053-3064.	0.6	50
224	Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. Blood, 2011, 118, 6087-6096.	0.6	121
225	Correction of Murine SCID-X1 by Lentiviral Gene Therapy Using a Codon-optimized IL2RG Gene and Minimal Pretransplant Conditioning. Molecular Therapy, 2011, 19, 1867-1877.	3.7	39
226	Comparison of the activity and pluripotency maintaining potential of human leukemia inhibitory factor (LIF) produced in E.coliand CHO cells. BMC Proceedings, 2011, 5, P109.	1.8	0
227	Production and purification of TGFb-1 in CHO-Cells. BMC Proceedings, 2011, 5, P134.	1.8	0
228	Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 426-435.	1.1	61
229	Lentiviral Vector Design and Imaging Approaches to Visualize the Early Stages of Cellular Reprogramming. Molecular Therapy, 2011, 19, 782-789.	3.7	224
230	Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Research, 2011, 39, 7147-7160.	6.5	62
231	Generation of Healthy Mice from Gene-Corrected Disease-Specific Induced Pluripotent Stem Cells. PLoS Biology, 2011, 9, e1001099.	2.6	50
232	Gammaretroviral Vectors: Biology, Technology and Application. Viruses, 2011, 3, 677-713.	1.5	111
233	Somatic Gene Therapy for X-Linked Severe Combined Immunodeficiency Using a Self-Inactivating Modified Gammaretroviral Vector Results in An Improved Preclinical Safety Profile and Early Clinical Efficacy in a Human Patient. Blood, 2011, 118, 164-164.	0.6	3
234	Use of the in Vitro Immortalization Assay to Quantify the Impact of Integration Spectrum and Vector Design on Insertional Mutagenesis. Blood, 2011, 118, 3123-3123.	0.6	1

#	Article	IF	Citations
235	Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins. Current Gene Therapy, 2011, 11, 382-398.	0.9	36
236	The Ubiquitous Chromatin Opening Element (UCOE) Enhances Lentiviral Cytidine Deaminase (CDD) Expression and Drug Resistance During Hematopoietic Differentiation of Murine Induced Pluripotent Stem Cells (iPSCs),. Blood, 2011, 118, 4179-4179.	0.6	3
237	Telomere Attrition and Chromosomal Instability During Long-Term Cultivation of Hematopoietic Stem Cells,. Blood, 2011, 118, 4001-4001.	0.6	0
238	Evidence for Cooperation of Receptor Tyrosine Kinases and Activating NOTCH Mutations to Hyperactivate mTOR in T-Cell Leukemia: A Rationale Basis for Targeted Therapy. Blood, 2011, 118, 1381-1381.	0.6	0
239	Gene-Correction Rescues Reprogramming of Fanconi Anemia Fibroblasts and Enables Hematopoietic Differentiation of FA Induced Pluripotent Stem Cells in Vitro and In Vivo. Blood, 2011, 118, 672-672.	0.6	0
240	Doxycycline Regulatable Expression of Cytidine Deaminase Mediates Myeloprotection and Avoids Lymphotoxicity in a Murine Transplant Model. Blood, 2011, 118, 2054-2054.	0.6	0
241	Deciphering the Role of Mir-99âˆ¼125 clusters in the Hematopoietic System. Blood, 2011, 118, 213-213.	0.6	3
242	Minicircle Performance Depending on S/MARâ€“Nuclear Matrix Interactions. Journal of Molecular Biology, 2010, 395, 950-965.	2.0	42
243	Self-Inactivating Alpharetroviral Vectors with a Split-Packaging Design. Journal of Virology, 2010, 84, 6626-6635.	1.5	56
244	Generation and genetic modification of induced pluripotent stem cells. Expert Opinion on Biological Therapy, 2010, 10, 1089-1103.	1.4	21
245	Multiplexing RMCE: Versatile Extensions of the Flp-Recombinase-Mediated Cassette-Exchange Technology. Journal of Molecular Biology, 2010, 402, 52-69.	2.0	65
246	Protein transduction from retroviral Gag precursors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7805-7810.	3.3	122
247	Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors. Molecular Therapy, 2009, 17, 1919-1928.	3.7	337
248	Transcriptional Enhancers Induce Insertional Gene Deregulation Independently From the Vector Type and Design. Molecular Therapy, 2009, 17, 851-856.	3.7	79
249	NAMPT is essential for the G-CSFâ€“induced myeloid differentiation via a NAD+â€“sirtuin-1â€“dependent pathway. Nature Medicine, 2009, 15, 151-158.	15.2	195
250	State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations. Current Gene Therapy, 2009, 9, 459-474.	0.9	109
251	Design and Production of Retro- and Lentiviral Vectors for Gene Expression in Hematopoietic Cells. Methods in Molecular Biology, 2009, 506, 191-205.	0.4	34
252	A Novel Mouse Model for RPS19-Deficient Diamond-Blackfan Anemia Locates the Erythroid Defect at CFU-E / Proerythroblast Transition.. Blood, 2009, 114, 178-178.	0.6	2

#	Article	IF	Citations
253	Cellular Restriction of Retrovirus Particle-Mediated mRNA Transfer. Journal of Virology, 2008, 82, 3069-3077.	1.5	23
254	Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors. Molecular Therapy, 2008, 16, 718-725.	3.7	255
255	Rapid Lentiviral Transduction Preserves the Engraftment Potential of Fancaâˆ’/âˆ’ Hematopoietic Stem Cells. Molecular Therapy, 2008, 16, 1154-1160.	3.7	38
256	Self-inactivating Gammaretroviral Vectors for Gene Therapy of X-linked Severe Combined Immunodeficiency. Molecular Therapy, 2008, 16, 590-598.	3.7	150
257	Clinical Application of Lentiviral Vectors â€“ Concepts and Practice. Current Gene Therapy, 2008, 8, 474-482.	0.9	82
258	Murine Embryonic Stem Cell-Derived Hepatic Progenitor Cells Engraft in Recipient Livers with Limited Capacity of Liver Tissue Formation. Cell Transplantation, 2008, 17, 313-323.	1.2	53
259	Production of High Titer cGMP-Grade SIN Gamma-Retroviral Vectors by Transfection in a Closed System Bioreactor. Blood, 2008, 112, 3539-3539.	0.6	0
260	Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood, 2007, 110, 1448-1457.	0.6	157
261	Improving Transcriptional Termination of Self-inactivating Gamma-retroviral and Lentiviral Vectors. Molecular Therapy, 2007, 15, 1167-1173.	3.7	118
262	Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. DNA Repair, 2007, 6, 1187-1196.	1.3	17
263	Retrovirus Vectors: Toward the Plentivirus?. Molecular Therapy, 2006, 13, 1050-1063.	3.7	90
264	Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood, 2006, 108, 2545-2553.	0.6	308
265	LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nature Medicine, 2006, 12, 1191-1197.	15.2	182
266	X-SCID transgene leukaemogenicity. Nature, 2006, 443, E5-E6.	13.7	144
267	Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Therapy, 2006, 13, 1524-1533.	2.3	135
268	Lentiviral vectors pseudotyped with murine ecotropic envelope: Increased biosafety and convenience in preclinical research. Experimental Hematology, 2006, 34, 588-592.	0.2	96
269	Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanineâ€“DNA methyltransferase in hematopoietic cells. Molecular Therapy, 2006, 13, 391-400.	3.7	172
270	LEF-1 Transcription Factor Regulates Proliferation and Differentiation of Myeloid Progenitors in Healthy Individuals and in Patients with Severe Congenital Neutropenia (CN).. Blood, 2005, 106, 390-390.	0.6	1

#	Article	IF	Citations
271	Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood, 2004, 104, 3543-3549.	0.6	59
272	Context Dependence of Different Modules for Posttranscriptional Enhancement of Gene Expression from Retroviral Vectors. Molecular Therapy, 2000, 2, 435-445.	3.7	188
273	Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a context-dependent manner. Nucleic Acids Research, 2000, 28, 901-910.	6.5	71
274	Chemoprotective Gene Delivery. , 0, , 377-391.		2